Cambridge Investment Research Advisors, Inc. Sesen Bio, Inc. Transaction History

Cambridge Investment Research Advisors, Inc.

$29.4 Billion
Q3 2024

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 08, 2023	SELL	$0.49 - $0.61 $19,649 - $24,461	-40,100 Reduced 29.72%	94,821 $58,000
Q2 2022 Jul 13, 2022	BUY	$0.38 - $0.89 $15,057 - $35,266	39,625 Added 41.58%	134,921 $109,000
Q1 2022 May 12, 2022	SELL	$0.58 - $0.86 $3,955 - $5,865	-6,820 Reduced 6.68%	95,296 $57,000
Q4 2021 Feb 03, 2022	SELL	$0.73 - $1.28 $730 - $1,280	-1,000 Reduced 0.97%	102,116 $83,000
Q3 2021 Nov 02, 2021	BUY	$0.77 - $4.91 $11,292 - $72,005	14,665 Added 16.58%	103,116 $81,000
Q2 2021 Aug 10, 2021	BUY	$2.18 - $4.66 $114,691 - $245,167	52,611 Added 146.79%	88,451 $408,000
Q1 2021 May 07, 2021	BUY	$1.3 - $3.24 $14,222 - $35,445	10,940 Added 43.94%	35,840 $93,000
Q1 2020 May 08, 2020	SELL	$0.39 - $1.03 $39 - $103	-100 Reduced 0.4%	24,900 $13,000
Q3 2019 Nov 06, 2019	BUY	$1.04 - $1.51 $4,264 - $6,191	4,100 Added 19.62%	25,000 $29,000
Q2 2019 Aug 15, 2019	BUY	$0.95 - $2.46 $19,855 - $51,414	20,900 New	20,900 $0

Others Institutions Holding SESN

# of Institutions

Shares Held

Call Options Held

Put Options Held

Concourse Financial Group Securities, Inc. Birmingham, AL

0
Shares

$0
0.0% of portfolio

View Full List

About Sesen Bio, Inc.

Ticker SESN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 201,702,000
Market Cap $127M
Description
Sesen Bio, Inc., a late-stage clinical company, focuses on designing, engineering, developing, and commercializing targeted fusion protein therapeutics (TFPTs) for the treatment patients with cancer. Its lead product candidates include Vicineum, a locally-administered targeted fusion protein that is in Phase III clinical trials for the treatment...

More about SESN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Cambridge Investment Research Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Cambridge Investment Research Advisors, Inc. with notifications on news.

Account